바이오스펙테이터

바이오스펙테이터 Jongwon Jang 기자

Kim Tae-han, CEO of Samsung BioLogics, has declared that he has completed the value chain for the entire biopharmaceutical production process from CDO, sCMO, CMO, and CRO. Based on these achievements, Samsung Biologics will establish the CDO R&D Center in San Francisco this year and enter the US market.

On 15th, Kim unveiled the plan in a presentation on the innovation and growth of Samsung in Biologics Industry at the JP Morgan Healthcare Conference in San Francisco, USA. .

The 38th annual JP Morgan Healthcare Conference is the world's largest bio investment event. Following last year, Samsung Biologics made a presentation at Grand Ballroom, the largest presentation venue on the main track. Samsung Biologics co-presented by CEO Kim Tae-han and Vice-President John Rim.

Kim announced that in 2017, Samsung Biologics began expanding its value chain to CDO / CRO and succeeded in establishing a one-stop service from cell line development to clinical substance production, quality control / analysis, and commercial mass production.

Samsung Biologics has the world's largest production scale (364 thousand liters) of CMO companies in seven years, and currently manufactures 35 CMO products, 47 product approvals, 45 CDO projects and 10 CRO projects. In particular, the company obtained 47 product approvals from FDA, EMA, PMDA, and HC.

Kim explained, “We have built an integrated CMO ecosystem by securing more than 9000 Biotech and Big Pharma as our main customer base and connecting with our customer base through CDO and CRO (Bio-safety Test Service).”

Samsung Biologics has started to secure a global foothold by establishing the CDO R&D Center in San Francisco this year. Samsung has carried out 45 CDO projects to date. In 2020, at least 18 projects will be added, aiming for more than 60 projects.

Vice president John Rim said, "Samsung Biologics is promoting synergy with customer satisfaction and production bases in Korea through overseas expansion. And we are continuing to look into further expansion in other parts of the U.S. and Europe”